How Do Cannabinoids Bind to Receptors? CB1 and CB2 Guide

Cannabinoids bind to receptors by settling into a pocket inside the receptor protein and holding there through weak, reversible forces such as hydrogen bonds and hydrophobic contacts. Nothing is welded together: the cannabinoid slides in, the receptor changes shape, and signaling proteins inside the cell switch on. The two primary targets are CB1 and CB2, both members of the G-protein coupled receptor (GPCR) family.

cannabinoid receptor antagonist drugs

Which Receptors Do Cannabinoids Target?

The endocannabinoid system has two classic receptor subtypes, plus several newer targets that researchers continue to map.

Cannabinoid Receptor Antagonist Drugs

• CB1: found mainly on neurons in the brain and central nervous system, plus some peripheral tissues. It is one of the most abundant GPCRs in the brain.
• CB2: found mostly on immune cells such as microglia, macrophages, and lymphocytes, with lower levels in the central nervous system.
• Other targets: TRPV1, GPR55, PPARs, and certain serotonin receptors, which help explain effects that CB1 and CB2 alone do not cover.

Step by Step: What Happens During Binding

1. Approach. Cannabinoids are fat-soluble molecules, so they travel through cell membranes and the lipid bilayer rather than floating only in watery fluid.
2. Entry. The ligand reaches the receptor's binding pocket, a cavity formed by the bundle of transmembrane helices.
3. Fit. Chemical groups on the cannabinoid line up with complementary groups in the pocket through van der Waals forces, hydrogen bonds, and hydrophobic interactions.
4. Shape change. The receptor shifts into an active conformation once the ligand is seated.
5. Signal. The activated receptor couples to a G protein (usually Gi/o), which then passes the message to enzymes and ion channels.

Because these interactions are non-covalent, binding is temporary. The cannabinoid can leave, and the receptor returns to its resting state, which is why effects rise and fade over time.

cb2 receptors and inflammation

Orthosteric vs. Allosteric Sites

Most cannabinoids that people discuss, including THC, act at the orthosteric site, meaning the same pocket the body's own endocannabinoids use. Anandamide and 2-AG are the natural ligands for that site, and they are made on demand and released in a retrograde fashion to influence nerve signaling.

CB2 Receptors and Inflammation

A second route exists at the allosteric site, a separate pocket on the receptor. A molecule binding there changes how strongly or how easily the main site responds. CBD is often described as a negative allosteric modulator at CB1, and it binds CB1 and CB2 with low affinity compared with THC.

Affinity, Efficacy, and Partial Agonists

• Affinity describes how tightly a cannabinoid holds the receptor.
• Efficacy describes how much signal it produces once bound.
• Agonist means the ligand activates the receptor; antagonist means it blocks; inverse agonist means it reduces activity below baseline.
• Partial agonist means it activates the receptor but not to the maximum. THC is widely classified as a partial agonist at CB1 and CB2.

This distinction matters. Two cannabinoids can attach to the same pocket yet produce noticeably different outcomes because of how efficiently each one switches the receptor on.

What Binding Triggers Inside the Cell

Once CB1 or CB2 activates, the coupled G protein splits into subunits that go on to:

• Inhibit adenylyl cyclase, lowering cyclic AMP levels.
• Modulate calcium and potassium channels, which changes how readily a neuron fires.
• Activate MAP kinase pathways tied to cell signaling and gene regulation.

CB1 activation tends to dampen neurotransmitter release at synapses. CB2 activation tends to influence immune cell activity and inflammation signaling.

What Shapes the Binding Outcome

Several variables influence how cannabinoids bind to receptors and what follows:

• Molecular structure: small changes in the cannabinoid skeleton alter how it seats in the pocket.
• Receptor density and location: a tissue with more CB1 will show a stronger response.
• Tolerance: repeated activation can reduce receptor numbers or sensitivity over time.
• Other compounds present: terpenes and minor cannabinoids may influence how a product feels, though human evidence on synergy is still developing.

Understanding this lock-and-key relationship explains why different cannabinoid products can produce different effects even at the same dose, and why receptor science remains central to cannabis research.